

PROVINCIAL FUNDING SUMMARY

Nab paclitaxel (Abraxane) for Metastatic Pancreatic Cancer (pCODR 10037)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: October 8, 2014

This information is current as of October 5, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs and cancer agencies for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2014	<p>Previously untreated locally advanced unresectable or metastatic pancreatic cancer Patients can have received gemcitabine in the adjuvant setting, ECOG 0 to 2, and age 18 to 75 years.</p> <p>A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment.</p>
AB	Funded	Mar 30, 2015	<p>Nab-paclitaxel plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas or patients unable to tolerate FOLFIRINOX. Not to be used after progression on FOLFIRINOX.</p> <p>February 3, 2016: for use in second line after progression on Folfirinox for patients with ECOG performance status 0-2.</p>

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	May 1, 2015	<p>In combination with Gemcitabine as a first line treatment option for patients with locally advanced unresectable or metastatic pancreas cancer who have an ECOG performance status of 0 to 2.</p> <p>Patients are not eligible for Abraxane® with Gemcitabine therapy in the second line setting for locally advanced unresectable or metastatic pancreas cancer if they previously received FOLFIRINOX as first line therapy and experienced disease progression. Conversely, patients who received Abraxane with Gemcitabine in the first line setting and experienced disease progression are not eligible for FOLFIRINOX in the second line setting.</p> <p>If patients exhibit intolerance to FOLFIRINOX therapy initiated in the first line setting without disease progression, a first line switch to Abraxane® with Gemcitabine therapy is approved.</p>
MB	Funded	Apr 20, 2015	<p>Nab-paclitaxel (Abraxane) plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with Karnofsky performance status of 100 to 70 (ECOG performance status 0 to 2) or for patients who are intolerant to first line treatment with FOLFIRINOX</p>

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Apr 17, 2015	<ul style="list-style-type: none"> •For the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with ECOG Performance Status of 0 to 2. •Funding for FOLFIRINOX or Abraxane is only permitted ONCE per patient throughout the course of their disease and must be given in the first-line setting. •Gemcitabine alone will continue to be an alternative in the first-line setting and will also be funded in the second line setting after FOLFIRINOX. •A patient's first-line regimen can be switched (from FOLFIRINOX to Abraxane or vice versa) due to documented toxicity/intolerance issues provided there has been no disease progression and the switch occurs within the first 3 months of initiating the first-line regimen. •On a time limited basis (6 months): Patients with locally advanced unresectable adenocarcinoma of the pancreas who initiated gemcitabine therapy prior to April 17, 2015 in the first-line setting and whose disease has not progressed, will have the option of adding Abraxane to their treatment regimen or switching to FOLFIRINOX. Patients with metastatic adenocarcinoma of the pancreas who initiated gemcitabine therapy prior to April 17, 2015 in the first-line setting and whose disease has not progressed, will have the option of adding Abraxane to their treatment regimen.
NS	Funded	Apr 1, 2015	In combination with gemcitabine as first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with an ECOG performance status (PS) of 0-2.
NB	Funded	July 15, 2015	In combination with gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with Karnofsky performance status of 100 to 70 (ECOG performance status 0 to 2) or for patients who are intolerant to first line treatment with FOLFIRINOX.
NL	Funded	Sept 1, 2015	In combination with gemcitabine for first-line treatment of locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients with ECOG 0-2.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
PEI	Funded	Aug 1, 2018	In combination with gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with an ECOG performance status of 0 to 2, or for patients who are intolerant to first line treatment with FOLFIRINOX.